Q1 Earnings Wire,
Thursday May 7, 2026
15 beats, 5 misses.
Beats
MBX, Beat 13.56 percent, MBX Biosciences Endocrine peptide platform. Canvuparatide chronic hypoparathyroidism, MBX 1416 post-bariatric hypoglycemia, MBX 4291 obesity. PBH cross-read with AMLX matters. Catalyst path is canvuparatide Phase 3 and MBX 1416 Phase 2.
NAMS, Beat 6.98 percent, NewAmsterdam Pharma Obicetrapib CETP inhibitor for cardiovascular and dyslipidemia. BROADWAY, BROOKLYN, TANDEM Phase 3 program is the entire story. Q1 print is noise relative to late 2026 to 2027 readout cadence.
Risk: CETP class scar tissue is real. Lilly’s evacetrapib failed REVEAL endpoints. Anacetrapib was abandoned. Obicetrapib has cleaner data but the class history weighs on the multiple.
CGEM, Beat 10.71 percent, Cullinan Therapeutics T cell engager autoimmune theme. CLN-978 CD19xCD3 EULAR June 6 initial SLE and RA data. Multi-dose RA Q3 2026, SjD Q4 2026. Velinotamig BCMAxCD3 autoimmune Phase 1 multi-dose Q4 2026. Zipalertinib NDA accepted, PDUFA February 27, 2027. Cash $393.3M, runway into 2029.
BEAM, Beat 7.14 percent, Beam Therapeutics Multiple shots on goal. BEAM-302 AATD pivotal cohort H2 2026, risto-cel sickle cell BLA as early as year-end 2026 with NEJM publication, BEAM-304 PKU IND 2026, BEAM-301 GSDIa initial data 2026. Cash $1.2B, runway into mid-2029. TIME100 Most Influential Companies designation.
Risk: Sickle cell competitive set is crowded with Vertex Casgevy and Bluebird Lyfgenia already approved. Risto-cel must differentiate on manufacturing and patient experience, not just clinical depth.
CSTL, Beat 2 percent, Castle Biosciences Q1 revenue $83.68M, EPS loss $0.49 vs $0.56 estimate, four straight quarters of revenue beats. Stock down 36.8 percent YTD versus S&P up 6 percent. Dermatology genomic testing platform commercial story. Need Q2 to confirm reacceleration.
Risk: YoY revenue down. Stock down 37 percent YTD for a reason, the trajectory is contested. Q2 confirms or breaks the thesis.
DCTH, Beat 62.50 percent, Delcath Systems HEPZATO KIT commercial ramp for hepatic uveal melanoma metastases. Clean beat suggests launch curve steepening. Liver-directed cancer therapy fits the spec pharma takeout playbook.
GYRE, Beat 35.71 percent, Gyre Therapeutics China specialty pharma. ETUARY pirfenidone commercial, Hydronidone NDA accepted China, Etuafusp Alfa in development. Liver fibrosis platform. China structure adds friction for Western buyers but commercial cash flow is real.
Warning: China structure is the discount. VIE structure, geopolitical risk, US delisting risk. Position size accordingly.
XERS, Beat 200 percent, Xeris Biopharma Recorlev levoketoconazole for Cushing’s, Gvoke ready-to-use glucagon, Keveyis for periodic paralysis. The 200 percent beat is mathematical noise off a small base, the underlying franchise growth is the real signal. Commercial-stage spec pharma in the takeout sweet spot.
LNTH, Beat 22.69 percent, Lantheus Holdings PYLARIFY PSMA PET imaging prostate cancer leader, DEFINITY contrast agent. Radiopharm pure-play in a sector consolidating fast. Clean balance sheet, real cash flow, multi-billion mcap, the kind of asset large pharma keeps running models on.
CVKD, Beat 33.33 percent, Cadrenal Therapeutics CAD-1005 12-LOX inhibitor for HIT. EOP2 minutes received, Phase 3 in 120 patients targeting NDA 2029. Phase 2 showed 25 percent absolute reduction in thrombotic events.
Warning: Cash math is the problem. $2.3M plus $2.5M April raise against a Phase 3 that costs $50M plus minimum. Every quarter is a structural dilution event until they secure real funding or partner. Microcap, illiquid, going concern risk.
ACRS, Beats by substance, Aclaris Therapeutics ATI-052 bispecific anti-TSLP and IL-4Rα Phase 1a SAD/MAD topline exceeded target, half-life approximately 45 days, complete and sustained inhibition. Quarterly dosing potential is the differentiation versus Tezspire every 4 weeks and Dupixent every 2 weeks. Phase 1b POC AD and asthma topline H2 2026, Phase 2b asthma Q4 2026. Cash $190.8M, runway through end of 2028.
Risk: Phase 1a is healthy volunteer data. Phase 1b POC reads in patients are the real test. The quarterly dosing claim is modeled, not yet demonstrated in disease.
CLYM, Beats by substance, Climb Bio Budoprutug anti-CD19 monoclonal antibody. SC formulation Phase 1 healthy volunteer data showed B-cell depletion comparable to IV. The convenience pivot the prescriber base wants in CD19 autoimmune. PrisMN Phase 2 pMN initial data Q4 2026 with FDA Fast Track. Phase 1b/2a ITP initial data June 2026. Global Phase 1b SLE data Q4 2026. CLYM116 anti-APRIL for IgAN reads ERA Congress June 2026. Cash $146.3M plus $110M April PIPE.
BDTX, Beats by substance, Black Diamond Therapeutics Silevertinib Phase 2 data oral presentation ASCO May 30 in frontline EGFRm NSCLC including DOR and PFS. Plus recurrent EGFRm NSCLC poster May 31 and EGFRvIII+ GBM trial-in-progress poster June 1. First patient dosed in Phase 2 GBM combination with temozolomide. Non-classical EGFRm NSCLC is the underserved subset where existing TKIs have weaker activity. Cash $118.3M into H2 2028.
Risk: Osimertinib is the entrenched standard. Silevertinib must show clear DOR and PFS advantage in non-classical mutations to take share, not just non-inferiority.
GLUE, Beats by substance, Monte Rosa Therapeutics Molecular glue degrader platform, three clinical programs approaching Phase 2. MRT-8102 NEK7-directed MGD interim GFORCE-1 showed 85 percent CRP reduction at 4 weeks, 94 percent below 2 mg/L threshold for reduced CVD risk. GFORCE-1 readout H2 2026, three Phase 2 initiations 2026 to 2027 across atherosclerotic risk, gout flares, hidradenitis suppurativa. MRT-6160 VAV1 MGD partnered with Novartis, up to $2.1B milestones plus 30 percent US profit share. MRT-2359 GSPT1 MGD ASCO GU showed 5 of 5 PSA responses in AR-mutant mCRPC, MODeFIRe-1 Phase 2 with apalutamide via J&J supply agreement Q3 2026. CCNE1 MGD IND H2 2026. Cash $671.2M into 2029.
Misses
AKBA, Miss 200 percent, Akebia Therapeutics Headline miss masks leading indicators. Vafseo Q1 net product revenue $15.8M, patient count up 60 percent QoQ, prescriber base up 28 percent to 1,025, prescriber diversification away from US Renal Care now at 30 percent, first refill adherence 86 percent. Auryxia generic erosion is the drag. VOCAL Phase 3b TIW data Q4 2026, VOICE Phase 4 early 2027. CEO bought 69,270 shares in March, the rare insider conviction signal in this batch. Cash $162.6M into two years.
Warning: Sub $2 stock. Limited institutional sponsorship, retail dominated, can drift on no news. HIF-PHI class scar tissue from FibroGen roxadustat US rejection and GSK daprodustat slow launch.
AMLX, Miss 8.82 percent, Amylyx Pharmaceuticals LUCIDITY Phase 3 PBH topline Q3 2026 is the only number that matters. 78 patients, 3:2 randomization, 16-week primary endpoint of Level 2 and Level 3 hypoglycemic event reduction. FDA-agreed primary endpoint. Five prior Phase 1 and Phase 2 trials all hit. AMX0114 ALS LUMINA biomarker data ENCALS June 2026. Cash $279.8M, runway into 2028.
Warning: RELYVRIO PHOENIX miss in 2024 is the overhang. Some institutional investors will not touch this name regardless of pivot. LUCIDITY is still a binary, miss takes the stock back to single digits.
GENB, Miss 122.92 percent, Generate Biomedicines AI-first generative biology platform. Just IPO’d February 27, 2026 at $16. Lead asset anti-TSLP for severe asthma plus broader ML-driven antibody and protein discovery pipeline. The miss size on a small base is post-IPO ramp noise, not a fundamental change. Platform validation reads remain the key catalyst path. Read across with ACRS bispecific anti-TSLP positions GENB lead asset in a competitive but still expanding TSLP class.
Warning: Fresh IPO, lockup expiration risk, no operating history as a public company, AI biology platform claims need clinical validation. High volatility, treat sizing accordingly.
HRMY, Miss 38.89 percent, Harmony Biosciences Wakix franchise the story, narcolepsy plus IH indication. The 38.89 percent miss is meaningful since HRMY is profitable, suggests script trajectory decelerated and pipeline ramp dragged the line. Pipeline diversification through ZYN002 Fragile X, BP1.15205 IH, and EPX-100 Dravet is the M&A appeal but none de-risked.
Warning: Pitolisant patent cliff timing is the structural overhang. Orexin agonist competitive setup from TAK-861 and ALKS 2680 is closing in. The miss for a profitable company is a signal, not noise.
VERA, Vera Therapeutics, beats by substance
Atacicept is the entire story and the catalyst is now four weeks out.
FDA granted Priority Review to the BLA for atacicept in IgAN, PDUFA July 7, 2026. US commercial launch mid-2026 pending approval. ORIGIN Phase 3 already hit the primary endpoint with statistically significant proteinuria reduction at week 36 in the prespecified interim, so accelerated approval is high probability not coin flip. Pivotal two-year eGFR data Q1 2027.
Atacicept is the dual mechanism BAFF plus APRIL TACI fusion protein. The differentiation in IgAN is real, Novartis Fabhalta hits factor B, Calliditas Tarpeyo is targeted budesonide, Travere Filspari is dual endothelin angiotensin antagonist, and Vera is the only approved-pending dual BAFF/APRIL targeted at the autoantibody driver upstream of the cascade. That positions atacicept for best-in-class disease modification rather than just symptom control.
PIONEER Phase 2 basket trial reads Q2 2026 in expanded IgAN populations plus anti-PLA2R primary membranous nephropathy plus anti-nephrin FSGS and minimal change disease. Each indication is an additional commercial leg if the basket reads.
Pre-commercial buildout is visible in the financials. Net loss $121M Q1 vs $51.7M YoY, cash burn doubled. New Chief Commercial Officer promoted, new Chief Legal Officer hired, new Board addition. That is a launch-ready posture, not a clinical-stage cost structure.
Cash $596.8M plus debt facility availability funds operations through approval and US launch and beyond. No raise overhang into the catalyst.
The cross-read with CLYM116 anti-APRIL platform matters here. APRIL is now a validated IgAN target post Vera, which lifts the entire next wave of B-cell targeted IgAN programs. CLYM benefits indirectly. AKBA AKB-097 basket study H2 2026 also benefits from the validation.
Risks to flag
IgAN market is now crowded with Fabhalta, Tarpeyo, and Filspari already approved. Atacicept must show clear differentiation on disease modification versus symptom control to take share, not just non-inferiority on proteinuria.
Launch execution risk is real for a first commercial drug. Sales force build, market access negotiations, payer coverage all need to come together in a compressed timeline mid-2026.
PDUFA July 7 is still a binary. Priority Review plus Breakthrough Therapy Designation plus a Phase 3 hit lowers the risk substantially but does not eliminate it. CRL on manufacturing or labeling questions is the tail risk.
Two-year eGFR data Q1 2027 is the long-term value driver. Accelerated approval is contingent on confirmatory data, and a mixed eGFR readout could reshape the commercial trajectory after launch.
IBRX, Miss 785.71 percent, ImmunityBio Headline number is mathematical noise. $632.8M net loss is mostly non-cash mark-to-market on warrants and derivatives because the stock ran. Adjusted net loss $86.2M is the real comp, up only $3.6M YoY. Underneath the print, ANKTIVA net product revenue $44.2M up 168 percent YoY, units up 168 percent, sequential growth 15 percent Q4 to Q1, NCCN Category 2A guideline expansion to BCG-unresponsive papillary-only NMIBC, BCG-naive CIS sBLA on track 2026. Commercial story is real.
Warning: Cap structure is broken. $1.5B total liabilities against $646M total assets, stockholders deficit $870M, related-party convertible note $678M, revenue interest liability $404M dominate the balance sheet. Soon-Shiong related party financing complicates any takeout. Minority shareholders sit behind related-party debt. This is the Dr. Pat playbook I warned about & got pushback on.
Summary takeaways
LNTH and DCTH are the cleanest commercial beats with real M&A optionality in the radiopharm and liver-directed oncology consolidation themes. CGEM, BEAM, ACRS, CLYM, BDTX, GLUE all deliver multi-shot platforms with 2026 catalyst paths. AKBA’s miss is misleading, leading indicators are accelerating and the CEO bought stock in March. AMLX’s miss is irrelevant, Q3 LUCIDITY readout is the only thing that matters. IBRX 785 percent miss is non-cash noise, ANKTIVA ramp is real but cap structure caps the takeout. CVKD’s beat is offset by a cash position that cannot fund the Phase 3 announced. GLUE molecular glue degrader platform with Novartis, Roche, J&J validations plus 5 of 5 mCRPC AR-mutant signal is the standout platform read of the morning.